New entity Elanco and Ginkgo focus on animal health breakthroughs based on microbiome science

The new company, called BiomEdit, is focused on developing products, including alternatives to antibiotics, that leverage microbiome science to improve animal health, animal protein production and disease monitoring in livestock. The teams will work on the discovery and production of new probiotics and bioactive molecules, as well as other products and services for breeders and veterinarians.

BiomEdit is launching with a targeted Series A fundraising of US$40 million, with participation from Viking Global Investors and Anterra Capital.

In exchange for their respective contributions of assets and intellectual property, Elanco and Ginkgo are expected to retain approximately 40% of the combined proportionate ownership of BiomEdit upon completion of the Series A financing. right to vote.

Antibiotic resistance, sustainability

In October 2021, Elanco announced plans to carve out a microbiome platform. BiomEdit is the result.

The partners plan to leverage Ginkgo’s cellular programming platform to improve the design and development of new products that address antibiotic resistance and improve livestock sustainability.

Elanco will contribute its intellectual property and a pipeline of ongoing programs to BiomEdit, which will be comprised of members of Elanco’s former microbiome R&D team.

Coupling the platform, pipeline and deep expertise of Elanco’s former microbiome team with Ginkgo’s unique strain screening and engineering capabilities will accelerate and amplify our ability to advance new animal microbiome-inspired products for animal health,”said Aaron Schacht, CEO of BiomEdit and former Elanco Executive Vice President of Innovation, Regulatory and Business Development.

Ginkgo claims “important know-how »​ in large-scale microbe discovery, design and monitoring for a wide range of functions. The animal health platform is the latest in a series of Boston-based biotech agribusinesses; others include Joyn Bio and Motif FoodWorks. Its biotechnology applications have also been adopted in the industrial chemical and pharmaceutical sectors.

Comments are closed.